Recursion Pharmaceuticals IncNASDAQ:RXRX
- LAST PRICE5.9250
- TODAY'S CHANGE (%)-0.0750 (-1.2500%)
- Bid / Lots5.9200/ 12
- Ask / Lots5.9300/ 31
- Open / Previous Close5.9700 / 6.0000
- Day Range
- 52 Week Range
- Volume1,827,254
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RXRX |
|---|---|---|
| 09:32 ET | 380094 | 5.985 |
| 09:33 ET | 66822 | 5.995 |
| 09:35 ET | 86516 | 5.93 |
| 09:37 ET | 174986 | 5.895 |
| 09:39 ET | 52046 | 5.91 |
| 09:42 ET | 138517 | 5.92 |
| 09:44 ET | 54943 | 5.92 |
| 09:46 ET | 62073 | 5.915 |
| 09:48 ET | 158211 | 5.9435 |
| 09:50 ET | 55754 | 5.91 |
| 09:51 ET | 86221 | 5.895 |
| 09:53 ET | 49708 | 5.894 |
| 09:55 ET | 44487 | 5.935 |
| 09:57 ET | 50502 | 5.91 |
| 10:00 ET | 21987 | 5.925 |
| 10:02 ET | 39309 | 5.925 |
Nov 20, 2024
DJ Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham, from 12:43PM ET on Wednesday Nov 20, 2024 by Dow Jones
12:43PM ET on Wednesday Nov 20, 2024 by Dow JonesRecursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 13, 2024
Press Release: Recursion and Exscientia Shareholders Approve the Proposed Combination, from 9:08AM ET on Wednesday Nov 13, 2024 by Dow Jones
9:08AM ET on Wednesday Nov 13, 2024 by Dow JonesRecursion and Exscientia Shareholders Approve the Proposed Combination, from 9:08AM ET on Wednesday Nov 13, 2024 by Dow Jones
9:08AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden, from 4:54PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:54PM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Recursion Pharmaceuticals Inc | 1.6B | -3.9x | --- |
Intellia Therapeutics Inc | 1.5B | -2.6x | --- |
Nurix Therapeutics Inc | 1.6B | -7.4x | --- |
Spyre Therapeutics Inc | 1.6B | -3.7x | --- |
Viridian Therapeutics Inc | 1.6B | -4.9x | --- |
Neumora Therapeutics Inc | 1.6B | -5.4x | --- |
Company Information
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Contact Information
- Headquarters
- 41S Rio Grande StreetSALT LAKE CITY, UT, United States 84101
- Phone
- 385-269-0203
- Fax
- 801-581-7895
Executives
- Independent Chairman of the Board
- Robert Hershberg
- President, Chief Executive Officer, Director
- Christopher Gibson
- Chief Financial Officer
- Ben Taylor
- Chief Operating Officer
- Kristen Rushton
- Senior Vice President - Head of Platform
- Lina Nilsson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $65.2M |
Shares Outstanding | 286.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-1.53 |
Book Value | $1.98 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 25.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -604.70% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
